“Let me start by saying that we continue to see strong performance with Eliquis. And this performance will continue throughout 2026.”

In context

“ng position as you alluded to with the late-stage pipeline. We don't need to chase deals. That said, we're going to continue to be looking out for opportunities to add strength and depth to our portfolio. In terms of the opportunities we're looking for, we've got a lot of opportunity to continue to build depth across each of our areas. So if an opportunity is in an area that we know well scientifically where we can add clinical or commercial value and ultimately deliver that value to patients the company and shareholders. We obviously have the financial ability and the muscle to. And so that's generally how we'll be approaching BD this year. And timing-wise, I think that obviously we're going to be opportunistic. Adam Lenkowsky? Adam Lenkowsky: Christopher Schott, thanks for the question. Let me start by saying that we continue to see strong performance with Eliquis. And this performance will continue throughout 2026. We have approximately 75% anorex share in the U.S. And we will continue to grow that. Now the broader pricing dynamics starting this year for Eliquis was the impetus for us to reevaluate our pricing strategy. And, of course, there's some pushes and pulls. Recall the IRA price was effectuated January 1, and this includes the removal of the Medicare Part D liability both in the initiation and in the catastrophic phase. We also finalized our $0 Medicaid agreement with administration and we took a step back and we're able to reassess our commercial contracting strategy as well. The roughly 40% WAC reduction eliminates inflationary penalties or CPI penalties of statutory rebates that have been accumulating over many years for the brand. And taken together, the continued increase in Eliquis mar”